TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Children’s Hospital of Orange County (CHOC) has generously contributed clinical trial data related to mucopolysaccharidosis (MPS), reinforcing the power of collaboration in advancing rare disease research.Continue reading
Author Archive: Roxan Olivas
C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies
TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled “Transforming Drug Development for Neurological Disorders: Proceedings from a Multi-disease Area Workshop,” now published in Neurotherapeutics, The Journal of the American Society for Experimental Neurotherapeutics.Continue reading
C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology
Research confirms immune-based therapies improve outcomes in new-onset T1DContinue reading
C-Path and CHI Announce Data Sharing Agreement
TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading nonprofit dedicated to improving the lives of children and adults living with Congenital Hyperinsulinism (HI), today announced a data sharing agreement to incorporate rare disease patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading
C-Path Announces Significant Expansion in Neonatal RWD Project
Details of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C.Continue reading
C-Path and EATRIS Join Forces with New Collaboration Agreement
AMSTERDAM and TUCSON, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastructure for Translational Medicine) are pleased to announce the signing of a collaboration agreement aimed at fostering actionable scientific and educational cooperation. Continue reading
C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource
The Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development.Continue reading
C-Path Welcomes Sanofi to its Type 1 Diabetes Consortium to Help Advance Drug Development
The global immunology and diabetes leader will collaborate with C-Path’s T1DC to drive transformative change in type 1 diabetes prevention and treatment.Continue reading
C-Path’s Duchenne Regulatory Science Consortium and Duchenne Data Foundation Announce Collaboration to Advance Solutions for Duchenne Muscular Dystrophy
TUCSON, Ariz. and VEENENDAAL, Netherlands, August 9, 2023 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) and the Duchenne Data Foundation (DDF) are excited to announce a joint collaboration aimed at advancing research and improving healthcare for individuals with Duchenne muscular dystrophy (DMD) and other dystrophinopathies (conditions linked to mutations in the DMD gene).Continue reading